A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.
Latest Information Update: 07 Aug 2019
At a glance
- Drugs Quetiapine (Primary)
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- Acronyms AMETHYST
- Sponsors AstraZeneca
- 31 Jul 2012 Results published in the International Clinical Psychopharmacology.
- 16 Sep 2009 Results of a secondary analysis investigating the effects of quetiapine on functioning and sleep quality have been presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
- 03 May 2008 Results have been presented at the 161st Annual Meeting of the American Psychiatric Association.